Physician profile
Laura E Wiese
NPI 1780806141
$3,992.88
in general payments reported to CMS, 2019-2025
18 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $167 · 2021: $358 · 2022: $584 · 2023: $658 · 2024: $1,141 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,200.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $892.65 | 2019-2025 | Precision 1, Dailies, Precision7 |
| Bausch & Lomb Americas INC. | $493.69 | 2022-2025 | Infuse, Xiidra, Miebo |
| Novartis Pharmaceuticals Corporation | $319.86 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $317.12 | 2019-2021 | |
| Oyster Point Pharma, INC. | $282.75 | 2023-2024 | Tyrvaya |
| Biotissue Holdings INC. | $273.70 | 2022-2025 | |
| Oculus, INC. | $235.09 | 2019 | |
| Coopervision INC. | $214.40 | 2020-2025 | Misight Contact Lens, Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $210.01 | 2020-2024 | Cequa |
| Tarsus Pharmaceuticals, INC. | $133.43 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $127.75 | 2021-2024 | |
| Lkc Technologies, INC. | $123.11 | 2024 | |
| Dompe US, INC. | $94.17 | 2025 | Oxervate |
| Carl Zeiss Meditec USA, INC. | $88.04 | 2022 | |
| Abbvie INC. | $80.09 | 2022-2025 | Vuity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $69.83 | 2025 | Idosetr |
| Harrow Eye, LLC | $19.40 | 2025 | Vevye |
| Allergan, INC. | $17.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Wiese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.